<DOC>
	<DOCNO>NCT01272128</DOCNO>
	<brief_summary>The primary objective ass quality life intramuscular ( IM ) Interferon Beta-1a participant relapse remit multiple sclerosis ( RRMS ) Clinically Isolated Syndrome ( CIS ) clinical practice setting .</brief_summary>
	<brief_title>Avonex-evaluation Quality Life Convenience Belgian Participants - The AVAIL Study</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Key Decision treat Interferon Beta1a ( IFN beta1a ) must precede enrollment , independently study compliance marketing authorization Study enrollment must occur prior 4th weekly administration IFN beta1a Able understand complete selfadministered questionnaire No contraindication IFN beta1a Key Subjects history hypersensitivity natural recombinant IFN beta component Subjects primary secondary progressive MS Subjects current severe depression and/or suicidal ideation Pregnant woman Subjects participate another clinical trial Subjects want participate study NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>